View ValuationMediPal Holdings 향후 성장Future 기준 점검 0/6MediPal Holdings (는) 각각 연간 2% 및 2.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 2.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 6.3% 로 예상됩니다.핵심 정보2.0%이익 성장률2.68%EPS 성장률Healthcare 이익 성장19.2%매출 성장률2.5%향후 자기자본이익률6.34%애널리스트 커버리지Low마지막 업데이트14 Jul 2026최근 향후 성장 업데이트공고 • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.모든 업데이트 보기Recent updates공고 • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.공고 • Jul 09MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. As of June 19, 2026, S.T. Corporation has resolved to tender its 339,000 shares. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation. MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders on July 7, 2026. A total of 24,466,104 shares were tendered, which was above the minimum number of shares to be purchased (8,676,100 shares). MediPal Holdings Corporation plans to implement a series of procedures to make the Tender Offeror the sole shareholder of Paltac Corporation (the “Squeeze-out Procedures”). Upon completion, the shares of Paltac Corporation will be delisted from the Prime Market of the Tokyo Stock Exchange.공고 • Jun 27MediPal Holdings Corporation to Report Q1, 2027 Results on Aug 05, 2026MediPal Holdings Corporation announced that they will report Q1, 2027 results on Aug 05, 2026공고 • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026.공고 • May 13MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation.공고 • May 10MediPal Holdings Corporation to Report Fiscal Year 2026 Results on May 14, 2026MediPal Holdings Corporation announced that they will report fiscal year 2026 results on May 14, 2026공고 • Feb 05Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥33.9 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent. Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others on February 3, 2025.공고 • Dec 16Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent.공고 • Nov 29MediPal Holdings Corporation to Report Q3, 2026 Results on Feb 09, 2026MediPal Holdings Corporation announced that they will report Q3, 2026 results on Feb 09, 2026공고 • Sep 30Medipal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of JapanMEDIPAL HOLDINGS Corporation and JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446, an investigational drug for the treatment of MPS IIIB (MPS IIIB or Sanfilippo syndrome type B). JCR was granted orphan drug designation for the treatment of MPS II by the U.S. Food and Drug Administration (FDA) in April 2025, and by the European Commission (EC) in June 2025. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo®? technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and it is currently being studied in a Phase I/II trial that is being conducted in Japan (JR-446-101) under a collaboration agreement between the two companies. In September 2023, MEDIPAL and JCR entered into a licensing agreement in which MEDIPAL will commercialize JR-446 for MPS IIIB outside of Japan. In addition, MEDIPAL will support JCR in the clinical development of JR-446 in Japan, including the distribution of investigational drugs, disease awareness, and clinical trial advancement. Both companies remain committed to developing a therapy for patients with MPS IIIB as swiftly as possible. Under the orphan drug designation system, the Ministry of Health, Labour & Welfare of Japan takes special measures to support and promote research activities for the development of drugs for rare diseases. Drugs satisfaction the following criteria may be designated as orphan drugs: they are targeting a condition with an incidence of fewer than 50,000 patients in Japan, or their intended use is for the treatment of a designated intractable disease. The drugs should be indicated for the treatment of serious diseases including difficult-to-treat diseases for which there are high unmet medical needs, such as there is no approved medicinal product or higher efficacy, or safety is expected compared with an approved medicinal product. Moreover, the application for orphan drug designation needs to have enough resources and plans for development of its product as an orphan drug in Japan. Mucopolysaccharidosis type IIIB, or Sanfilippo Syndrome type B, is an autosomal recessive disease caused by pathogenic mutations in the NAGLU gene, encoding a lysosomal enzyme involved in the degradation of heparan sulfate. With the accumulation of heparan sulfate in the central nervous system in the brain, individuals with this condition present rapid neurological decline, including sleep disorders, loss of speech, and behavioral changes, which may significantly affect the quality of life of patients and their families.공고 • Aug 27MediPal Holdings Corporation to Report Q2, 2026 Results on Nov 05, 2025MediPal Holdings Corporation announced that they will report Q2, 2026 results on Nov 05, 2025공고 • Jun 29MediPal Holdings Corporation to Report Q1, 2026 Results on Aug 05, 2025MediPal Holdings Corporation announced that they will report Q1, 2026 results on Aug 05, 2025공고 • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 4,000,000 shares, representing 1.92% for ¥8,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 1.92% of its issued share capital (excluding treasury stock), for ¥8,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until October 31, 2025. As of April 30, 2025, the company had 207,950,180 shares in issue (excluding treasury stock) and 11,275,862 shares in treasury.공고 • May 13MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025.공고 • Mar 01MediPal Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025MediPal Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025공고 • Dec 03+ 1 more updateMediPal Holdings Corporation to Report Q3, 2025 Results on Feb 06, 2025MediPal Holdings Corporation announced that they will report Q3, 2025 results on Feb 06, 2025공고 • Aug 27MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024MediPal Holdings Corporation announced that they will report Q2, 2025 results on Nov 01, 2024공고 • Jul 01MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIBMediPal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. announced the completion of the regulatory review by the Pharmaceuticals and Medical Devices Agency (PMDA) for the clinical trial notification for the phase I/II study of JR-446, a blood-brain barrier-penetrating a-N-acetylglucosaminidase, for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome type B), a devastating and ultra-rare lysosomal storage disorder. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo technology, has shown promising preclinical results in addressing the symptoms of this challenging disorder. In September 2023, MEDIPAL and JCR secured a license to commercialize JR-446 overseas and partnered to develop and commercialize it in Japan, targeting MPS IIIB2. With the regulatory review now complete, company plan to start the clinical trial in Japan in the first half of fiscal 2024 (April to September). This collaboration highlights the commitment of MEDIPAL and JCR to pioneer treatments for ultrarare diseases. By advancing therapies like JR-446, company aim to bring hope to patients and their families, while enhancing corporate value and contributing to a society where everyone can live with physical and mental well-being.공고 • Jun 06MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024MediPal Holdings Corporation announced that they will report Q1, 2025 results on Aug 01, 2024공고 • Jun 01MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) on May 31, 2024.공고 • May 16MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024.공고 • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 2,500,000 shares, representing 1.19% of its issued share capital (excluding treasury stock), for ¥5,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until August 30, 2024. As of April 30, 2024, the company had 210,016,973 shares in issue (excluding treasury stock) and 11,274,369 shares in treasury.공고 • May 01MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.공고 • Mar 02MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024MediPal Holdings Corporation announced that they will report fiscal year 2024 results on May 14, 2024공고 • Nov 27MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024MediPal Holdings Corporation announced that they will report Q3, 2024 results on Feb 05, 2024공고 • Aug 30MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023MediPal Holdings Corporation announced that they will report Q2, 2024 results on Nov 02, 2023공고 • May 31MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023MediPal Holdings Corporation announced that they will report Q1, 2024 results on Aug 02, 2023공고 • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023.공고 • Nov 30MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023MediPal Holdings Corporation announced that they will report Q3, 2023 results on Feb 01, 2023이익 및 매출 성장 예측OTCPK:MEPD.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/20294,101,29041,18254,00064,49233/31/20284,024,20541,91948,09662,09153/31/20273,920,06540,687108,000118,00053/31/20263,817,35442,53436,86546,552N/A12/31/20253,775,82341,455N/AN/AN/A9/30/20253,744,21840,64234,13444,228N/A6/30/20253,707,17040,857N/AN/AN/A3/31/20253,671,32840,27948,12860,559N/A12/31/20243,650,98949,426N/AN/AN/A9/30/20243,604,41546,04756,72572,460N/A6/30/20243,581,31239,294N/AN/AN/A3/31/20243,558,73241,47442,44861,843N/A12/31/20233,507,50537,244N/AN/AN/A9/30/20233,453,60138,63640,54356,888N/A6/30/20233,408,41741,724N/AN/AN/A3/31/20233,360,00838,8062,64216,146N/A12/31/20223,351,06930,439N/AN/AN/A9/30/20223,333,07328,22211,52326,954N/A6/30/20223,304,37228,248N/AN/AN/A3/31/20223,290,92129,42342,33961,216N/A12/31/20213,279,58336,411N/AN/AN/A9/30/20213,265,95130,52325,25945,124N/A6/30/20213,241,83826,468N/AN/AN/A3/31/20213,211,12523,92618,78034,448N/A12/31/20203,208,23726,682N/AN/AN/A9/30/20203,186,65133,32958,48884,718N/A6/30/20203,236,31537,002N/AN/AN/A3/31/20203,253,07937,96829,56556,917N/A12/31/20193,242,84034,722N/AN/AN/A9/30/20193,253,49535,443N/A33,428N/A6/30/20193,189,61334,116N/AN/AN/A3/31/20193,181,92834,359N/A63,716N/A12/31/20183,178,57834,315N/AN/AN/A9/30/20183,169,34434,122N/A75,079N/A6/30/20183,169,21637,166N/AN/AN/A3/31/20183,146,31434,780N/A63,558N/A12/31/20173,124,72433,199N/AN/AN/A9/30/20173,093,74331,086N/A45,376N/A6/30/20173,072,59726,239N/AN/AN/A3/31/20173,063,90029,011N/A47,954N/A12/31/20163,065,83332,149N/AN/AN/A9/30/20163,072,86832,201N/A53,535N/A6/30/20163,057,50133,965N/AN/AN/A3/31/20163,028,18730,771N/A21,985N/A12/31/20152,995,21028,449N/AN/AN/A9/30/20152,953,70726,052N/A25,185N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MEPD.F 의 연간 예상 수익 증가율(2%)이 saving rate(3.5%) 미만입니다.수익 vs 시장: MEPD.F 의 연간 수익(2%)이 US 시장(17.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: MEPD.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: MEPD.F 의 수익(연간 2.5%)이 US 시장(연간 12.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: MEPD.F 의 수익(연간 2.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MEPD.F의 자본 수익률은 3년 후 6.3%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/18 03:16종가2026/06/01 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MediPal Holdings Corporation는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Atsushi SekiBarclaysRitsuo WatanabeBofA Global ResearchHidemaru YamaguchiCitigroup Inc6명의 분석가 더 보기
공고 • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.
공고 • Jul 15Medipal Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027MediPal Holdings Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2027. For the year, the company expects net sales of ¥3,944,000 million, operating profit of ¥53,500 million compared to previous guidance of ¥55,000 million, profit attributable to owners of parent of ¥43,000 million compared to previous guidance of ¥39,000 million and earnings per share of ¥210.06 compared to previous guidance of ¥190.52. The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze- out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026. As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent. Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.
공고 • Jul 09MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. As of June 19, 2026, S.T. Corporation has resolved to tender its 339,000 shares. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation. MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders on July 7, 2026. A total of 24,466,104 shares were tendered, which was above the minimum number of shares to be purchased (8,676,100 shares). MediPal Holdings Corporation plans to implement a series of procedures to make the Tender Offeror the sole shareholder of Paltac Corporation (the “Squeeze-out Procedures”). Upon completion, the shares of Paltac Corporation will be delisted from the Prime Market of the Tokyo Stock Exchange.
공고 • Jun 27MediPal Holdings Corporation to Report Q1, 2027 Results on Aug 05, 2026MediPal Holdings Corporation announced that they will report Q1, 2027 results on Aug 05, 2026
공고 • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2026.
공고 • May 13MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion.MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from State Street Bank & Trust Company 505103, JP Morgan Chase Bank 385632, State Street Bank & Trust Company 505001 Obayashi Group, BNYM AS Agt CLTS 10 Percent, BBH For Fidelity Low-Priced STOCK Fund and NORTHERN TRUST CO. (AVFC) RE FIDELITY FUNDS for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026. Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation.
공고 • May 10MediPal Holdings Corporation to Report Fiscal Year 2026 Results on May 14, 2026MediPal Holdings Corporation announced that they will report fiscal year 2026 results on May 14, 2026
공고 • Feb 05Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥33.9 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent. Nippon Life Insurance Company completed the acquisition of 52.34% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others on February 3, 2025.
공고 • Dec 16Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion.Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. (TSE:3902) from MediPal Holdings Corporation (TSE:7459), Hiroyuki Iwasaki and others for ¥40.4 billion on December 15, 2025. A cash consideration valued at ¥1 per right and valued at ¥1693 per share will be paid by Nippon Life Insurance Company. As part of consideration, ¥3706 is paid towards Fourth Series of Share Acquisition Rights, ¥1400 is paid towards Fifth Series of Share Acquisition Rights and ¥40.4 billion is paid towards common equity of Medical Data Vision Co., Ltd. In a related transaction, Nippon Life Insurance Company is acquiring 37.81% stake in Medical Data Vision Co., Ltd. from SBI Holdings, Inc. Upon completion of the transactions, Nippon Life Insurance Company will hold 100% stake in Medical Data Vision Co., Ltd. The transaction is subject to minimum tender. The expected completion of the transaction is February 3, 2026. SMBC Nikko Securities Inc. acted as tender offer agent.
공고 • Nov 29MediPal Holdings Corporation to Report Q3, 2026 Results on Feb 09, 2026MediPal Holdings Corporation announced that they will report Q3, 2026 results on Feb 09, 2026
공고 • Sep 30Medipal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of JapanMEDIPAL HOLDINGS Corporation and JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan has granted orphan drug designation to JR-446, an investigational drug for the treatment of MPS IIIB (MPS IIIB or Sanfilippo syndrome type B). JCR was granted orphan drug designation for the treatment of MPS II by the U.S. Food and Drug Administration (FDA) in April 2025, and by the European Commission (EC) in June 2025. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system (CNS) symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo®? technology, has shown promising non-clinical results in addressing the CNS symptoms of this challenging disorder, and it is currently being studied in a Phase I/II trial that is being conducted in Japan (JR-446-101) under a collaboration agreement between the two companies. In September 2023, MEDIPAL and JCR entered into a licensing agreement in which MEDIPAL will commercialize JR-446 for MPS IIIB outside of Japan. In addition, MEDIPAL will support JCR in the clinical development of JR-446 in Japan, including the distribution of investigational drugs, disease awareness, and clinical trial advancement. Both companies remain committed to developing a therapy for patients with MPS IIIB as swiftly as possible. Under the orphan drug designation system, the Ministry of Health, Labour & Welfare of Japan takes special measures to support and promote research activities for the development of drugs for rare diseases. Drugs satisfaction the following criteria may be designated as orphan drugs: they are targeting a condition with an incidence of fewer than 50,000 patients in Japan, or their intended use is for the treatment of a designated intractable disease. The drugs should be indicated for the treatment of serious diseases including difficult-to-treat diseases for which there are high unmet medical needs, such as there is no approved medicinal product or higher efficacy, or safety is expected compared with an approved medicinal product. Moreover, the application for orphan drug designation needs to have enough resources and plans for development of its product as an orphan drug in Japan. Mucopolysaccharidosis type IIIB, or Sanfilippo Syndrome type B, is an autosomal recessive disease caused by pathogenic mutations in the NAGLU gene, encoding a lysosomal enzyme involved in the degradation of heparan sulfate. With the accumulation of heparan sulfate in the central nervous system in the brain, individuals with this condition present rapid neurological decline, including sleep disorders, loss of speech, and behavioral changes, which may significantly affect the quality of life of patients and their families.
공고 • Aug 27MediPal Holdings Corporation to Report Q2, 2026 Results on Nov 05, 2025MediPal Holdings Corporation announced that they will report Q2, 2026 results on Nov 05, 2025
공고 • Jun 29MediPal Holdings Corporation to Report Q1, 2026 Results on Aug 05, 2025MediPal Holdings Corporation announced that they will report Q1, 2026 results on Aug 05, 2025
공고 • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 4,000,000 shares, representing 1.92% for ¥8,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 1.92% of its issued share capital (excluding treasury stock), for ¥8,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until October 31, 2025. As of April 30, 2025, the company had 207,950,180 shares in issue (excluding treasury stock) and 11,275,862 shares in treasury.
공고 • May 13MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2025.
공고 • Mar 01MediPal Holdings Corporation to Report Fiscal Year 2025 Results on May 13, 2025MediPal Holdings Corporation announced that they will report fiscal year 2025 results on May 13, 2025
공고 • Dec 03+ 1 more updateMediPal Holdings Corporation to Report Q3, 2025 Results on Feb 06, 2025MediPal Holdings Corporation announced that they will report Q3, 2025 results on Feb 06, 2025
공고 • Aug 27MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024MediPal Holdings Corporation announced that they will report Q2, 2025 results on Nov 01, 2024
공고 • Jul 01MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIBMediPal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. announced the completion of the regulatory review by the Pharmaceuticals and Medical Devices Agency (PMDA) for the clinical trial notification for the phase I/II study of JR-446, a blood-brain barrier-penetrating a-N-acetylglucosaminidase, for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome type B), a devastating and ultra-rare lysosomal storage disorder. MPS IIIB affects an estimated 500 to 1,000 individuals worldwide, causing severe central nervous system symptoms. Despite the dire need, there are currently no approved treatments available for this condition. JR-446, developed using JCR's proprietary J-Brain Cargo technology, has shown promising preclinical results in addressing the symptoms of this challenging disorder. In September 2023, MEDIPAL and JCR secured a license to commercialize JR-446 overseas and partnered to develop and commercialize it in Japan, targeting MPS IIIB2. With the regulatory review now complete, company plan to start the clinical trial in Japan in the first half of fiscal 2024 (April to September). This collaboration highlights the commitment of MEDIPAL and JCR to pioneer treatments for ultrarare diseases. By advancing therapies like JR-446, company aim to bring hope to patients and their families, while enhancing corporate value and contributing to a society where everyone can live with physical and mental well-being.
공고 • Jun 06MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024MediPal Holdings Corporation announced that they will report Q1, 2025 results on Aug 01, 2024
공고 • Jun 01MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) on May 31, 2024.
공고 • May 16MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024.
공고 • May 15MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.MediPal Holdings Corporation (TSE:7459) announces a share repurchase program. Under the program, the company will repurchase up to 2,500,000 shares, representing 1.19% of its issued share capital (excluding treasury stock), for ¥5,000 million. The purpose of the program is to improve capital efficiency through shareholder returns. The repurchased shares will be cancelled. The program will run until August 30, 2024. As of April 30, 2024, the company had 210,016,973 shares in issue (excluding treasury stock) and 11,274,369 shares in treasury.
공고 • May 01MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion on April 30, 2024. Transaction has already been approved by Noritsu Koki's board of director's. Transaction is expected to complete on May 31, 2024.
공고 • Mar 02MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024MediPal Holdings Corporation announced that they will report fiscal year 2024 results on May 14, 2024
공고 • Nov 27MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024MediPal Holdings Corporation announced that they will report Q3, 2024 results on Feb 05, 2024
공고 • Aug 30MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023MediPal Holdings Corporation announced that they will report Q2, 2024 results on Nov 02, 2023
공고 • May 31MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023MediPal Holdings Corporation announced that they will report Q1, 2024 results on Aug 02, 2023
공고 • May 14MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023.
공고 • Nov 30MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023MediPal Holdings Corporation announced that they will report Q3, 2023 results on Feb 01, 2023